When was Areteia founded?

Areteia was founded in 2022 and raised its 1st funding round within a year of its incorporation.

Where is Areteia located?

Areteia is headquartered in Durham, United States.

How many employees does Areteia have?

As of Mar 01, 2026, the latest employee count at Areteia is 10 - 49.

Is Areteia a funded company?

Areteia is a funded company, having raised a total of $435M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 15, 2022.

When was the latest funding round of Areteia?

Areteia's latest funding was a $***** Series A round on Feb 13, 2024, with participation from 10 investors. Its primary sector is Pulmonology. In United States, the Pulmonology sector has seen $928M in funding in 2026 to date.

Where does Areteia rank among its competitors?

Areteia ranks 2nd amongst 11 active competitors, of which 6 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Kinaset Therapeutics, which secured $103M in Jan, 2026.

Who are the top competitors of Areteia?

Areteia's top competitors include Kinaset Therapeutics, Sitryx and DeepCure. Among them, Kinaset Therapeutics secured the most recent funding round in January, 2026.

Areteia - 2026 Company Profile, Team, Funding & Competitors

Areteia is a series A company based in Durham (United States), founded in 2022. It operates as a Developer of therapeutics for eosinophilic asthma. Areteia has raised $435M in funding from Bain Capital Life Sciences. The company has 11 active competitors, including 6 that are funded. Its top competitors include companies like Kinaset Therapeutics, Sitryx and DeepCure.

Company Details

Developer of therapeutics for eosinophilic asthma. It offers dexpramipexole an oral medicine that inhibits the maturation of eosinophils that causes damage to the bronchi and treats eosinophilic asthma.

Website: areteiatx.com
Email ID: *****@areteiatx.com

Key Metrics

Founded Year

2022

Location

Durham, United States

Stage

Series A

Total Funding

$435M in 2 rounds

Latest Funding Round

Series A, Feb 13, 2024, $*****

Investors

Bain Capital Life Sciences & 9 more

Ranked

2^nd among 11 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

Kinaset Therapeutics & 12 more

View Areteia's full profile

Areteia is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Areteia Therapeutics, Inc. CIN: 88-2037001 , United States, Active	Apr 21, 2022	-	-	-

Areteia has raised a total funding of $435M over 2 rounds. Its first funding round was on Jun 15, 2022. Its latest funding round was a Series A round on Feb 13, 2024 for $*****. 10 investors participated in its latest round. Areteia has 10 institutional investors.

Here is the list of recent funding rounds of Areteia:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 13, 2024	3759089	Series A	4013057	8528067	1689154	7420355
Jun 15, 2022	4464018	Series A	4478502	3038349	Bain Capital Life Sciences	Google Ventures & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of Areteia's funding rounds and investors

Areteia's employee count trend

Areteia has 10 - 49 employees as of Mar 26. Here is Areteia's employee count trend over the years:

Uncover Areteia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Areteia include Kinaset Therapeutics, Sitryx and DeepCure. Here is the list of Top 10 competitors of Areteia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Kinaset Therapeutics 2020, Boston (United States), Series B	Developer of therapeutics to treat asthma	$172M	RA Capital Management, Atlas Venture & 9 others	55/100
2nd	Areteia 2022, Durham (United States), Series A	Developer of therapeutics for eosinophilic asthma	$435M	Bain Capital Life Sciences, Access Industries ... & 8 others	54/100
3rd	Sitryx 2018, Oxford (United Kingdom), Series B	Biotechnology company focused on immunometabolism, developing therapies	$109M	SV Health Investors, Lilly & 5 others	53/100
4th	DeepCure 2018, Boston (United States), Series A	Developer of novel small molecule therapies for immune diseases	$64.6M	IAG Capital Partners, Morningside & 5 others	49/100
5th	Auron Therapeutics 2018, Wellesley (United States), Series B	Developer of cancer therapeutics for the treatment of blood cancer	$118M	Mubadala, Qiming & 12 others	48/100
6th	Atopia Therapeutics 2016, Geneva (Switzerland), Unfunded	Developer of therapeutics for asthma and other allergic diseases	-	-	39/100
7th	Oxagen 1996, Abingdon (United Kingdom), Deadpooled	Developer of drugs for inflammatory and respiratory diseases	$86.5M	Bessemer Venture Partners, Advent Life Sciences ... & 8 others	30/100
8th	Pantherics 2017, San Diego (United States), Funding Raised	Developer of therapeutics for respiratory disorders	-	NIH, HHS	30/100
9th	HpVac 2016, Geneva (Switzerland), Unfunded	Developer of therapeutics for immunological disorders	-	-	26/100
10th	GBC-HpVac 2016, Geneva (Switzerland), Unfunded	Developer of a drug for allergic diseases and asthma	-	-	26/100